Trial Profile
A 12-week Study to Evaluate the 24 Hour Pulmonary Function of Fluticasone Furoate (FF)/Vilanterol Inhalation Powder (FF/VI Inhalation Powder) Once Daily Compared With Salmeterol/Fluticasone Propionate (FP) Inhalation Powder Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 08 Oct 2021
Price :
$35
*
At a glance
- Drugs Vilanterol/fluticasone furoate (Primary) ; Salmeterol/fluticasone propionate
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline
- 29 Jun 2019 Results of post hoc analysis of exploratory genome-wide genetic analysis from 10 trials (NCT01772134, NCT01772147, NCT00633217, NCT01817764, NCT01879410, NCT01822899, NCT01323621, NCT01342913, NCT01323634, and NCT01706328)published in the Respiratory Medicine
- 05 Sep 2012 Results presented at the 22nd Annual Congress of the European Respiratory Society.
- 27 Apr 2012 Actual patient number 531 added as reported by ClinicalTrials.gov.